Summary:
A clinical research study for people with schizophrenia.
The purpose of the Journey Studies is to find out how safe the study drug is, how well the body handles taking it (tolerability), and how well it works as an add-on therapy in study participants with schizophrenia who did not respond well enough to antipsychotic therapy. These studies will determine the effectiveness of the study drug, called valbenazine, on symptoms of schizophrenia. This study aims to find out how well the study drug works compared to a placebo as an add-on therapy in participants who still experience symptoms. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients. The first dose of treatment will occur up to 4 weeks after the screening visit, and the follow-up period will be approximately 2 weeks following a participant’s final dose.
Eligibility Criteria:
Key inclusion criteria for this study:
- Be male or female aged ≥ 13 years old
- Be diagnosed with schizophrenia for at least 1 year prior to the start of the research study
- Be receiving a daily dose of antipsychotic therapy (other than clozapine)
- Have a history of not responding well to antipsychotic treatment
Other protocol-defined inclusion and exclusion criteria may apply.